Insulin glargine (Toujeo) vs insulin icodec

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline

Insulin glargine (Toujeo)

Marketed by Sanofi

Approved in Type 2 Diabetespeptide
Partial signal

NCT01499082 · Phase 3 · completed

The trial was large and randomized, with an active insulin glargine comparator, and its primary HbA1c endpoint was a hard clinical treatment measure that met the prespecified non-inferiority margin. However, treatment was open-label rather than double-blinded, so the evidence is considered moderate despite the favorable non-inferiority result.

Reported efficacy

Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061) (met)

Result source: NCT01499082

insulin icodec · Awiqli

Marketed by Novo Nordisk

Approved in Type 2 Diabetespeptide
Partial signal

NCT04760626 · Phase 3 · completed

The study was randomized and actively controlled, but it was open-label, with 542 participants assigned to insulin icodec and 543 to once-daily basal insulin analogues. The primary HbA1c endpoint was met for non-inferiority, but HbA1c is a surrogate measure rather than a hard clinical or endoscopic endpoint, supporting a moderate evidence grade.

Next expected readout: October 2027 · NCT07747402 (registry estimate)

Reported efficacy

Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Insulin Icodec -0.84 Percentage (%) point (Standard Deviation 0.83) vs Insulin Glargine -0.58 Percentage (%) point (Standard Deviation 0.89) (met)

Result source: NCT06340854

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointInsulin glargine (Toujeo)insulin icodec
HbA1c, change—Not reported-1.7% vs -1.3%vs Once Daily Basal Insulin Analoguewk 52 · n 542NCT04760626
11 other results
  • -1.6% vs -1.4% wk 52 · n 492 · Phase 3 · primary NCT04460885
  • -0.8% vs -0.6% wk 26 · n 204 · Phase 3 · primary NCT06340854
  • -1.6% vs -1.4% wk 26 · n 294 · Phase 3 · primary NCT04795531
  • -0.9% vs -0.7% wk 26 · n 263 · Phase 3 · primary NCT04770532
  • -1.2% vs -1.2% wk 26 · n 291 · Phase 3 · primary NCT04880850
  • -1.3% vs -1.1% wk 26 · n 122 · Phase 2 · primary NCT03751657
  • -0.5% vs -0.5% wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • -0.8% vs -0.5% wk 16 · n 54 · Phase 2 · secondary NCT03922750
  • -1% vs -1.0% wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -1.2% vs -1.0% wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -1.4% vs -1.0% wk 16 · n 52 · Phase 2 · secondary NCT03951805
Body weight, change (kg)—Not reported2.3 vs 1.8vs Insulin Glarginewk 52 · n 492NCT04460885
10 other results
  • 2.0 vs 0.6 wk 26 · n 204 · Phase 3 · secondary NCT06340854
  • 2.8 vs 2.3 wk 26 · n 294 · Phase 3 · secondary NCT04795531
  • 1.4 vs -0.3 wk 26 · n 263 · Phase 3 · secondary NCT04770532
  • 2.7 vs 2.2 wk 26 · n 291 · Phase 3 · secondary NCT04880850
  • 1.5 vs 1.6 wk 26 · n 122 · Phase 2 · secondary NCT03751657
  • 1.3 vs 0.1 wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • 0.6 vs 0.1 wk 16 · n 54 · Phase 2 · secondary NCT03922750
  • 0.9 vs 0.6 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • 1.1 vs 0.6 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • 1.3 vs 0.6 wk 16 · n 52 · Phase 2 · secondary NCT03951805
HbA1c below 7%—Not reported—Not posted · NCT05013229
Fasting plasma glucose, change—Not reported-3.4 vs -3.3vs Insulin Glarginewk 52 · n 480NCT04460885
9 other results
  • -3.0 vs -3.0 wk 26 · n 284 · Phase 3 · secondary NCT04795531
  • -1.6 vs -1.6 wk 26 · n 260 · Phase 3 · secondary NCT04770532
  • -1.8 vs -1.6 wk 26 · n 283 · Phase 3 · secondary NCT04880850
  • -3.2 vs -3.0 wk 26 · n 121 · Phase 2 · secondary NCT03751657
  • -0.8 vs -0.6 wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • -0.7 vs -0.6 wk 16 · n 52 · Phase 2 · secondary NCT03922750
  • -2.2 vs -2.3 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -2.4 vs -2.3 wk 16 · n 50 · Phase 2 · secondary NCT03951805
  • -3.0 vs -2.3 wk 16 · n 51 · Phase 2 · secondary NCT03951805
3-point MACE (% with event)—Not reported—Not posted · NCT05013229

HbA1c, change

Insulin glargine (Toujeo)
—Not reported
insulin icodec
-1.7% vs -1.3%vs Once Daily Basal Insulin Analoguewk 52 · n 542NCT04760626
11 other results
  • -1.6% vs -1.4% wk 52 · n 492 · Phase 3 · primary NCT04460885
  • -0.8% vs -0.6% wk 26 · n 204 · Phase 3 · primary NCT06340854
  • -1.6% vs -1.4% wk 26 · n 294 · Phase 3 · primary NCT04795531
  • -0.9% vs -0.7% wk 26 · n 263 · Phase 3 · primary NCT04770532
  • -1.2% vs -1.2% wk 26 · n 291 · Phase 3 · primary NCT04880850
  • -1.3% vs -1.1% wk 26 · n 122 · Phase 2 · primary NCT03751657
  • -0.5% vs -0.5% wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • -0.8% vs -0.5% wk 16 · n 54 · Phase 2 · secondary NCT03922750
  • -1% vs -1.0% wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -1.2% vs -1.0% wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -1.4% vs -1.0% wk 16 · n 52 · Phase 2 · secondary NCT03951805

Body weight, change (kg)

Insulin glargine (Toujeo)
—Not reported
insulin icodec
2.3 vs 1.8vs Insulin Glarginewk 52 · n 492NCT04460885
10 other results
  • 2.0 vs 0.6 wk 26 · n 204 · Phase 3 · secondary NCT06340854
  • 2.8 vs 2.3 wk 26 · n 294 · Phase 3 · secondary NCT04795531
  • 1.4 vs -0.3 wk 26 · n 263 · Phase 3 · secondary NCT04770532
  • 2.7 vs 2.2 wk 26 · n 291 · Phase 3 · secondary NCT04880850
  • 1.5 vs 1.6 wk 26 · n 122 · Phase 2 · secondary NCT03751657
  • 1.3 vs 0.1 wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • 0.6 vs 0.1 wk 16 · n 54 · Phase 2 · secondary NCT03922750
  • 0.9 vs 0.6 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • 1.1 vs 0.6 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • 1.3 vs 0.6 wk 16 · n 52 · Phase 2 · secondary NCT03951805

HbA1c below 7%

Insulin glargine (Toujeo)
—Not reported
insulin icodec
—Not posted · NCT05013229

Fasting plasma glucose, change

Insulin glargine (Toujeo)
—Not reported
insulin icodec
-3.4 vs -3.3vs Insulin Glarginewk 52 · n 480NCT04460885
9 other results
  • -3.0 vs -3.0 wk 26 · n 284 · Phase 3 · secondary NCT04795531
  • -1.6 vs -1.6 wk 26 · n 260 · Phase 3 · secondary NCT04770532
  • -1.8 vs -1.6 wk 26 · n 283 · Phase 3 · secondary NCT04880850
  • -3.2 vs -3.0 wk 26 · n 121 · Phase 2 · secondary NCT03751657
  • -0.8 vs -0.6 wk 16 · n 50 · Phase 2 · secondary NCT03922750
  • -0.7 vs -0.6 wk 16 · n 52 · Phase 2 · secondary NCT03922750
  • -2.2 vs -2.3 wk 16 · n 51 · Phase 2 · secondary NCT03951805
  • -2.4 vs -2.3 wk 16 · n 50 · Phase 2 · secondary NCT03951805
  • -3.0 vs -2.3 wk 16 · n 51 · Phase 2 · secondary NCT03951805

3-point MACE (% with event)

Insulin glargine (Toujeo)
—Not reported
insulin icodec
—Not posted · NCT05013229
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety

Coverage. Insulin glargine (Toujeo): 8 of 8 rows · insulin icodec: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricInsulin glargine (Toujeo)
Rows use multiple source trials
insulin icodec
Rows use multiple source trials
Fasting Plasma Glucose
absolute change · mmol/L
No placebo or comparator arm
-2.66 mmol/L @ 52wk*a,b,c
NCT02451137 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -48 mg/dL as posted
-1.29 mmol/L @ 52wka,b,c
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
HbA1c
absolute change · percentage points
No placebo or comparator arm
-1.29% (n=1651) @ 52wka,b,c
NCT02451137 · Phase 4 · registry result, not featured evidence
-1.23% (n=91) @ 52wka,b,c
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
Time in Range
absolute value · percentage points
50.3% (n=92) vs 54.9% (n=84) Glargine U100 @ 12wka,b,c,d
NCT03013985 · Phase 4 · registry result, not featured evidence
71.94% (n=439) vs 66.9% (n=440) Insulin Glargine @ 52wka,b,c,d
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Weight
absolute change · kg
No placebo or comparator arm
1.51 kg @ 52wka,b,c
NCT02451137 · Phase 4 · registry result, not featured evidence
-3.85 kg @ 52wka,b,c
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
Dropout rate
14.8%e
NCT03013985 · Phase 4 · registry result, not featured evidence
show 1 more result
14.9%
NCT02451137 · Phase 4 · registry result, not featured evidence
8.3%f
NCT04760626 · Phase 3
show 14 more results
3.7%
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0%
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
2%
NCT04795531 · Phase 3
1.1%
NCT04770532 · Phase 3
5.5%
NCT04880850 · Phase 3
36.5%Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
2%
NCT05823948 · Phase 3 · registry result, not featured evidence
1.9%Insulin 287 (With 100% Loading Dos
NCT03922750 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Without Loading Dose)
NCT03922750 · Phase 2 · registry result, not featured evidence
2.4%
NCT03751657 · Phase 2 · registry result, not featured evidence
2%Insulin 287 (Titration Algorithm A
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm B
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm C
NCT03951805 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—e
NCT03013985 · Phase 4 · registry result, not featured evidence
show 1 more result
2.6%
NCT02451137 · Phase 4 · registry result, not featured evidence
—f
NCT04760626 · Phase 3
show 14 more results
—
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
—
NCT04795531 · Phase 3
—
NCT04770532 · Phase 3
—
NCT04880850 · Phase 3
—Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
—
NCT05823948 · Phase 3 · registry result, not featured evidence
1.9%Insulin 287 (With 100% Loading Dos
NCT03922750 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Without Loading Dose)
NCT03922750 · Phase 2 · registry result, not featured evidence
—
NCT03751657 · Phase 2 · registry result, not featured evidence
2%Insulin 287 (Titration Algorithm A
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm B
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm C
NCT03951805 · Phase 2 · registry result, not featured evidence
Serious AEs
19.4%e
NCT03013985 · Phase 4 · registry result, not featured evidence
show 1 more result
9.8%
NCT02451137 · Phase 4 · registry result, not featured evidence
8.3%f
NCT04760626 · Phase 3
show 14 more results
13%
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
7.8%
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
5.1%
NCT04795531 · Phase 3
8.4%
NCT04770532 · Phase 3
7.6%
NCT04880850 · Phase 3
—Insulin Icodec + Semaglutide
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
3.2%Insulin Icodec + Semaglutide: Trea
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
3.9%
NCT05823948 · Phase 3 · registry result, not featured evidence
3.7%Insulin 287 (With 100% Loading Dos
NCT03922750 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Without Loading Dose)
NCT03922750 · Phase 2 · registry result, not featured evidence
1.6%
NCT03751657 · Phase 2 · registry result, not featured evidence
5.9%Insulin 287 (Titration Algorithm A
NCT03951805 · Phase 2 · registry result, not featured evidence
2%Insulin 287 (Titration Algorithm B
NCT03951805 · Phase 2 · registry result, not featured evidence
0%Insulin 287 (Titration Algorithm C
NCT03951805 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
e
trauma 3.7%
cough 0.9%
gastroparesis 0.9%
NCT03013985 · Phase 4 · registry result, not featured evidence
f
covid-19 7.9%
NCT04760626 · Phase 3
show 13 more results
covid-19 17.7%
back pain 8.1%
diarrhoea 7.9%
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
nasopharyngitis 13.6%
diarrhoea 5.3%
diabetic retinopathy 2.9%
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
covid-19 8.2%
diabetic retinopathy 5.1%
influenza 5.1%
NCT04795531 · Phase 3
nasopharyngitis 8.4%
diarrhoea 5.3%
headache 5.3%
NCT04770532 · Phase 3
covid-19 8.6%
diarrhoea 5.2%
diabetic retinopathy 4.1%
NCT04880850 · Phase 3
nausea 19.1%
vomiting 8.5%
upper respiratory tract infection 7.4%
NCT05813912 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 13.7%
covid-19 9.8%
back pain 7.8%
NCT05823948 · Phase 3 · registry result, not featured evidence
nasopharyngitis 14.8%
medical device site haemorrhage 9.3%
headache 5.6%
NCT03922750 · Phase 2 · registry result, not featured evidence
nasopharyngitis 14%
hypertension 6%
influenza 6%
NCT03922750 · Phase 2 · registry result, not featured evidence
headache 11.2%
nasopharyngitis 8%
upper respiratory tract infection 5.6%
NCT03751657 · Phase 2 · registry result, not featured evidence
back pain 9.8%
nasopharyngitis 9.8%
headache 0%
NCT03951805 · Phase 2 · registry result, not featured evidence
nasopharyngitis 13.7%
headache 5.9%
back pain 3.9%
NCT03951805 · Phase 2 · registry result, not featured evidence
headache 9.6%
nasopharyngitis 3.8%
back pain 1.9%
NCT03951805 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 3 versus Phase 4.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 52 weeks versus 12 weeks.
  5. ePopulation comparability has not been reviewed for these studies.
  6. fPopulation comparability has not been reviewed for 13 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Insulin glargine (Toujeo)

Daily Glucose mg/dL 10.32 vs 10.21 Glargine U100 mmol/L
absolute value · mmol/L
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 186 mg/dL as posted
show 6 more results
9.52 vs 9.13 Glargine U100 mmol/L @ 12wk*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 171.6 mg/dL as posted
8.33 vs 7.46 Glargine U100 mmol/L @ 12wk*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 150 mg/dL as posted
8.45 vs 8.64 Glargine U100 mmol/L @ 12wk*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 152.3 mg/dL as posted
9.42 vs 10.92 Glargine U100 mmol/L*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 169.71 mg/dL as posted
10.74 vs 10.75 Glargine U100 mmol/L*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 193.53 mg/dL as posted
10.46 vs 9.69 Glargine U100 mmol/L*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 188.46 mg/dL as posted
Hypoglycemia Event Incidence 8.7% (n=92) vs 9.5% (n=84) Glargine U100 @ 12wk
responder rate · % of participants
NCT03013985 · Phase 4 · registry result, not featured evidence
Severe Hypoglycemia Event Incidence 0% (n=92) vs 6% (n=84) Glargine U100 @ 12wk
responder rate · % of participants
NCT03013985 · Phase 4 · registry result, not featured evidence
HbA1c Target Attainment Without Hypoglycemia 31.3% (n=1651) @ 26wk
responder rate · % of participants
No placebo or comparator arm
NCT02451137 · Phase 4 · registry result, not featured evidence
show 1 more result
37.3% (n=1651) @ 26wk
NCT02451137 · Phase 4 · registry result, not featured evidence

insulin icodec

HbA1c -1.68% (n=542) vs -1.31% (n=542) Once Daily Basal Insulin Analogue @ 52wk
absolute change · percentage points
NCT04760626 · Phase 3
show 11 more results
-1.55% (n=492) vs -1.35% (n=492) Insulin Glargine @ 52wk
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-0.84% (n=204) vs -0.58% (n=201) Insulin Glargine @ 26wk
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.57% (n=294) vs -1.36% (n=294) Insulin Degludec @ 26wk
NCT04795531 · Phase 3
-0.93% (n=263) vs -0.71% (n=263) Insulin Degludec @ 26wk
NCT04770532 · Phase 3
-1.16% (n=291) vs -1.18% (n=291) Insulin Glargine @ 26wk
NCT04880850 · Phase 3
-0.47% (n=50) vs -0.54% (n=50) Insulin Glargine U100 @ 16wk
NCT03922750 · Phase 2 · registry result, not featured evidence
-0.77% (n=54) vs -0.54% (n=50) Insulin Glargine U100 @ 16wk
NCT03922750 · Phase 2 · registry result, not featured evidence
-1.33% (n=122) vs -1.15% (n=120) Insulin Glargine @ 26wk
NCT03751657 · Phase 2 · registry result, not featured evidence
-1% (n=51) vs -1.02% (n=51) Insulin Glargine @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
-1.22% (n=51) vs -1.02% (n=51) Insulin Glargine @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
-1.38% (n=52) vs -1.02% (n=51) Insulin Glargine @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
Fasting Plasma Glucose -3.35 vs -3.33 Insulin Glargine mmol/L @ 52wk
absolute change · mmol/L
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 9 more results
-3.01 vs -2.99 Insulin Degludec mmol/L @ 26wk
NCT04795531 · Phase 3
-1.58 vs -1.62 Insulin Degludec mmol/L @ 26wk
NCT04770532 · Phase 3
-1.75 vs -1.61 Insulin Glargine mmol/L @ 26wk
NCT04880850 · Phase 3
-0.83 vs -0.57 Insulin Glargine U100 mmol/L @ 16wk
NCT03922750 · Phase 2 · registry result, not featured evidence
-0.69 vs -0.57 Insulin Glargine U100 mmol/L @ 16wk
NCT03922750 · Phase 2 · registry result, not featured evidence
-3.2 vs -2.99 Insulin Glargine mmol/L @ 26wk
NCT03751657 · Phase 2 · registry result, not featured evidence
-2.23 vs -2.34 Insulin Glargine mmol/L @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
-2.42 vs -2.34 Insulin Glargine mmol/L @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
-3.01 vs -2.34 Insulin Glargine mmol/L @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
Weight 2.29 vs 1.83 Insulin Glargine kg @ 52wk
absolute change · kg
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 10 more results
2.04 vs 0.55 Insulin Glargine kg @ 26wk
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.77 vs 2.32 Insulin Degludec kg @ 26wk
NCT04795531 · Phase 3
1.4 vs -0.3 Insulin Degludec kg @ 26wk
NCT04770532 · Phase 3
2.73 vs 2.16 Insulin Glargine kg @ 26wk
NCT04880850 · Phase 3
1.32 vs 0.1 Insulin Glargine U100 kg @ 16wk
NCT03922750 · Phase 2 · registry result, not featured evidence
0.61 vs 0.1 Insulin Glargine U100 kg @ 16wk
NCT03922750 · Phase 2 · registry result, not featured evidence
1.49 vs 1.56 Insulin Glargine kg @ 26wk
NCT03751657 · Phase 2 · registry result, not featured evidence
0.87 vs 0.63 Insulin Glargine kg @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
1.11 vs 0.63 Insulin Glargine kg @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
1.25 vs 0.63 Insulin Glargine kg @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
Time Below Range 0.27 vs 0.21 Insulin Glargine % of time @ 52wk
absolute value · % of time
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Time Above Range 26.86 vs 32.27 Insulin Glargine % of time @ 52wk
absolute value · % of time
NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
35.52 vs 39.71 Insulin Degludec % of time @ 26wk
NCT04770532 · Phase 3
30.47 vs 31.3 Insulin Glargine % of time @ 26wk
NCT04880850 · Phase 3
Time Above Range -20.54% (n=202) vs -11.19% (n=198) Insulin Glargine @ 26wk
absolute value · percentage points
NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3
Hypoglycemia Episodes Level 3 0 vs 2 Insulin Degludec count @ 31wk
event count · count
NCT04795531 · Phase 3
show 3 more results
0 vs 0 Insulin Degludec count @ 26wk
NCT04795531 · Phase 3
0 vs 1 Insulin Degludec count @ 31wk
NCT04770532 · Phase 3
7 vs 3 Insulin Glargine count @ 31wk
NCT04880850 · Phase 3
Hypoglycemia Episodes Level 2 53 vs 23 Insulin Degludec count @ 31wk
event count · count
NCT04795531 · Phase 3
show 3 more results
50 vs 17 Insulin Degludec count @ 26wk
NCT04795531 · Phase 3
113 vs 41 Insulin Degludec count @ 31wk
NCT04770532 · Phase 3
937 vs 935 Insulin Glargine count @ 31wk
NCT04880850 · Phase 3
Hypoglycemia Episodes Level 2 or 3 53 vs 25 Insulin Degludec count @ 31wk
event count · count
NCT04795531 · Phase 3
show 3 more results
50 vs 17 Insulin Degludec count @ 26wk
NCT04795531 · Phase 3
113 vs 42 Insulin Degludec count @ 31wk
NCT04770532 · Phase 3
944 vs 938 Insulin Glargine count @ 31wk
NCT04880850 · Phase 3
DTSQs 4.22 vs 2.96 Insulin Degludec score @ 26wk
absolute change · score
NCT04770532 · Phase 3
Time Below 54 mg/dL 0.34% (n=238) vs 0.22% (n=239) Insulin Degludec @ 26wk
absolute value · percentage points
NCT04770532 · Phase 3
Time in Range 66.88 vs 66.44 Insulin Glargine % of time @ 26wk
absolute value · % of time
NCT04880850 · Phase 3
show 5 more results
65.99 vs 64.98 Insulin Glargine U100 % of time @ 16wk
NCT03922750 · Phase 2 · registry result, not featured evidence
72.86 vs 64.98 Insulin Glargine U100 % of time @ 16wk
NCT03922750 · Phase 2 · registry result, not featured evidence
76.65 vs 75.89 Insulin Glargine % of time @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
82.97 vs 75.89 Insulin Glargine % of time @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence
80.89 vs 75.89 Insulin Glargine % of time @ 16wk
NCT03951805 · Phase 2 · registry result, not featured evidence

+ 5 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin glargine (Toujeo)'s landscape · insulin icodec's landscape